Author: gonzalo (Juan CV)

COVID-19 VACCINES AND NEUROMUSCULAR DISEASES, 23
4 de May de 20214 de May de 2021
Post

COVID-19 VACCINES AND NEUROMUSCULAR DISEASES, 23

On February 23rd, 2021, we participated in one of the seminars organized by ASEM Catalonia: COVID-19 vaccine and neuromuscular diseases, a virtual lecture given by Dr. Olivé, neurologist at Sant Pau University Hospital and Dr. Natera, neuropediatrician at the Sant Joan de Déu University Hospital in Barcelona. Here you will find a summary of the...

An update on potential adjuvant therapies in Collagen VI CMD: Alisporivir, Givinostat and Omigapil
30 de March de 20216 de October de 2021
Post

An update on potential adjuvant therapies in Collagen VI CMD: Alisporivir, Givinostat and Omigapil

In recent years, news have emerged from time to time that point to the potential benefit of some drugs for congenital muscular dystrophy patients. Although they do not hope to cure the disease, these drugs do seek to alleviate the harmful effects that a dysfunctional collagen matrix causes on muscle cells, slowly promoting their destruction....

Personalized medicine for Collagen VI Congenital Muscular Dystrophies
Project

Personalized medicine for Collagen VI Congenital Muscular Dystrophies

Project description: Congenital Muscular Dystrophies are a group of rare, highly disabling neuromuscular diseases with a reduced life expectancy. Over the last 10 years, the work of the research team led by Dr. C. Jiménez, from the Sant Joan de Déu University Hospital in Barcelona, ​​has focused on collagen VI related-diseases (COL6-RD), which it is...

Update of the international patient registry of Congenital Muscular Dystrophies (CMDIR)
Project

Update of the international patient registry of Congenital Muscular Dystrophies (CMDIR)

Project description: The International Registry of Congenital Muscular Dystrophies (CMDIR) was created in 2009 by CureCMD, a patient association of the United States, in collaboration with a group of other organizations, with the aim of identifying the global population of patients with congenital muscular dystrophies (CMD), which, among others, include collagen-VI CMD. The primary objectives...